Core Insights - The collaboration between Innovent Biologics and Takeda Pharmaceutical aims to leverage Innovent's strengths in tumor immunology (IO) and antibody-drug conjugates (ADC) alongside Takeda's extensive experience in global oncology drug development to accelerate the global development of Innovent's late-stage pipeline drugs [1] Group 1: Collaboration Details - Innovent and Takeda will jointly develop the next-generation IO cornerstone therapy IBI363 (PD-1/IL-2α-bias) and will co-commercialize it in the United States, with Takeda leading the development under a collaborative governance structure [1] - Innovent grants Takeda commercialization rights for IBI363 outside Greater China and the United States [1] - Takeda receives exclusive rights for IBI343 (CLDN18.2 ADC) outside Greater China and an exclusive option for IBI3001 (EGFR/B7H3 ADC) outside Greater China [1] Group 2: Financial Terms - Innovent will receive an upfront payment of $1.2 billion, which includes a $100 million premium strategic equity investment, along with potential milestone payments, bringing the total deal value to up to $11.4 billion [1] - Innovent will also receive a share of sales from the collaboration [1]

Core Viewpoint - The article highlights a significant surge in the innovative drug sector, driven by a strategic collaboration between Innovent Biologics and Takeda Pharmaceutical, which could lead to a total transaction value of up to $11.4 billion (approximately 81.2 billion RMB) [3][5]. Group 1: Market Performance - On October 22, A-shares and Hong Kong stocks related to innovative drugs experienced a strong rally, with several stocks like Innovent Biologics and Haisco Pharmaceutical hitting the daily limit [4]. - The global oncology drug market has surpassed $200 billion, with the expiration of PD-1 patents creating new competitive opportunities [6]. Group 2: Strategic Collaboration - Innovent Biologics announced a global strategic partnership with Takeda to accelerate the development of next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies [4][6]. - The collaboration includes two late-stage therapies, IBI363 and IBI343, and an early-stage project, IBI3001, with Takeda leading the global development and commercialization efforts outside of Greater China and the U.S. [4][5]. Group 3: Financial Implications - Innovent Biologics will receive an upfront payment of $1.2 billion, including a strategic equity investment of $100 million, and could earn up to $10.2 billion in potential milestone payments [5]. - The partnership is expected to significantly enhance Takeda's oncology pipeline, which has faced challenges in recent years [6]. Group 4: Industry Trends - The trend of Chinese innovative drugs entering international markets continues, with contract values exceeding $100 billion in the first three quarters of the year, marking a 170% year-on-year increase [7]. - The fourth quarter is anticipated to see an acceleration in business development (BD) activities, with major pharmaceutical companies likely to allocate their annual budgets during this period [8].

Core Insights - The collaboration between Innovent Biologics and Takeda Pharmaceutical marks a significant global strategic partnership aimed at accelerating the development of next-generation IO and ADC therapies for cancer treatment, with a total transaction value potentially reaching $11.4 billion [2][4]. Financial Details - Takeda will make an upfront payment of $1.2 billion to Innovent, which includes a strategic equity investment of $100 million at a subscription price of HKD 112.56 per share, representing a 20% premium over the weighted average share price of Innovent over the past 30 trading days [4]. - The total potential milestone payments for the development and sales of IBI363, IBI343, and IBI3001 could amount to approximately $10.2 billion, with the overall transaction value reaching up to $11.4 billion [4]. Drug Development and Commercialization - **IBI363**: A globally innovative PD-1/IL-2α-bias bispecific antibody fusion protein in Phase III clinical trials, showing strong anti-tumor activity. Innovent and Takeda will share development costs and profits in the U.S. on a 40/60 basis [5]. - **IBI343**: A best-in-class CLDN18.2 ADC in Phase III clinical trials, with Takeda granted exclusive global rights for development, production, and commercialization outside Greater China, focusing on first-line gastric and pancreatic cancer treatments [6]. - **IBI3001**: A pioneering EGFR/B7H3 dual antibody ADC in Phase I clinical trials, with Takeda having the option for exclusive global rights outside Greater China, contingent on payment of an exercise fee and potential milestone payments [7]. Strategic Importance - For Takeda, this collaboration is a crucial step in strengthening its oncology pipeline and positioning itself in the post-PD-1 era, with IBI363 and IBI343 identified as "disruptive cancer therapies" and key growth drivers for the company beyond 2030 [8].

Group 1 - The collaboration represents a trend of partnerships between Chinese companies and international pharmaceutical firms aiming to enhance their global presence [1] - The initiative focuses on leveraging promising drug development pipelines that are emerging in China [1]

10月22日，科创创新药ETF国泰（589720）盘中涨超1.5%。 消息面，10月22日早，信达生物与武田达成全球战略合作。 科创创新药ETF国泰（589720）聚焦科创板创新药企业，跟踪汇聚30家代表性优质公司的上证科创板创 新药指数，以高成长biotech为主，产品20%涨跌幅限制使其更贴合板块波动。从业绩表现来看，"924行 情"以来，上证科创板创新药指数跑赢恒生港股通创新药指数！2024年9月24日至2025年9月30日市场反 弹期间，上证科创板创新药指数和恒生港股通创新药指数涨幅分别为117.04%和109.62%，上证科创板 创新药指数或有助于在市场风险偏好回升时更好地分享科创板的弹性。 （文章来源：每日经济新闻） 相关机构表示，BD旺季有望验证板块韧性，四季度为创新药BD交易高峰期，占全年交易占比约40%。 信达此次百亿级合作的落地，打响四季度BD行情的"头炮"。上周ESMO大会中国创新药已抢先释放数 据价值，本次BD有望印证筹码结构与交易预期消化后的修复动力。11月国家医保谈判决定新药院内放 量速度，12月商保创新药目录或破解高价药"入院难"问题，与医保形成互补。明年1月JP Morgan医 ...

Core Viewpoint - The strategic collaboration between Innovent Biologics and Takeda Pharmaceutical, valued at $11.4 billion, marks a significant milestone in China's innovative drug sector, aiming to penetrate the global oncology market [1][3]. Group 1: Collaboration Details - Innovent will receive an upfront payment of $1.2 billion, which includes a $100 million premium for strategic equity investment, along with potential milestone payments and a high sales revenue share [1][3]. - This partnership is the first of its kind for a domestic pipeline to engage in "global co-development" with a multinational giant, targeting the $200 billion global oncology market [3][5]. Group 2: Pipeline Focus - The collaboration centers on two innovative pipelines: IBI363 and IBI343, which have been previously discussed in industry conferences and reports as potential next-generation oncology drugs [5][6]. - IBI363 targets the PD-1 upgrade market, addressing key issues such as efficacy in PD-1 resistant patients and expanding the applicability of immunotherapy to "cold tumors" like pancreatic and liver cancers [8][10]. - IBI343 focuses on precision treatment for gastrointestinal cancers, with a significant objective response rate of 58%, far exceeding traditional chemotherapy [10][13]. Group 3: Strategic Implications - Takeda's investment aims to fill the market gap during the PD-1 patent expiration phase, betting on the differentiated potential of Innovent's pipelines as future growth engines [6][8]. - Innovent's involvement in clinical design and commercialization decisions through a global co-development model enhances its long-term capabilities in global trial operations and market access [13]. - The partnership exemplifies the alignment of China's innovative drug capabilities with multinational commercialization expertise, positioning Innovent as a key player in defining new competitive landscapes in the global market [13].

Core Viewpoint - Innovent Biologics has entered into an $11.4 billion partnership with Takeda Pharmaceutical to enhance the development of its immuno-oncology and antibody-drug conjugate therapies [1] Company Summary - The deal with Takeda is aimed at accelerating the development of Innovent's immuno-oncology and antibody-drug conjugate products [1] - This collaboration signifies a strategic move for Innovent to leverage Takeda's expertise and resources in the pharmaceutical sector [1] Industry Summary - The partnership highlights the growing trend of collaborations in the biopharmaceutical industry, particularly in the fields of immuno-oncology and targeted therapies [1] - Such large-scale deals reflect the increasing investment and interest in innovative cancer treatments within the global pharmaceutical market [1]

Core Insights - Innovent Biologics has entered a strategic global collaboration with Takeda to advance next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) cancer therapies aimed at developing transformative cancer treatments for patients worldwide [1][2]. Collaboration Details - The partnership will focus on several investigational medicines within Innovent's IO+ADC pipeline, including IBI363, IBI343, and IBI3001, with IBI363 currently in Phase 3 clinical stage [2][4]. - Innovent and Takeda will co-develop IBI363 globally, sharing development costs at a ratio of 40/60, and will co-commercialize it in the U.S. [5][7]. - Takeda will receive exclusive commercialization rights for IBI343 outside Greater China, while also having an option for IBI3001 [5][10]. Financial Aspects - Innovent will receive an upfront payment of US$1.2 billion, which includes a strategic equity investment of US$100 million at a 20% premium to the average share price [13][14]. - The total deal value could reach up to US$11.4 billion, including potential milestone payments and royalties [14]. Product Highlights - IBI363 is a first-in-class PD-1/IL-2 bispecific antibody fusion protein that has shown promising results in clinical trials, particularly in immunotherapy-resistant lung cancer [4][6]. - IBI343 is an innovative ADC targeting CLDN18.2, currently in Phase 3 trials for gastric and gastroesophageal cancers, and has received Breakthrough Designation in China [9][10]. - IBI3001 is a first-in-class bispecific ADC targeting B7-H3 and EGFR, currently in Phase 1 clinical trials [11][12]. Strategic Goals - The collaboration aims to redefine cancer treatment globally by leveraging Innovent's R&D capabilities and Takeda's extensive experience in drug development and commercialization [3][5]. - This partnership is a significant step in Innovent's strategic roadmap to expand its global footprint and enhance its position as a leading biopharmaceutical company [3].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告僅供參考之用，並不構成收購、購買或認購本公司任何證券之邀請或要約。 信達生物制藥 本公告由本公司根據香港聯合交易所有限公司證券上市規則第13.09條及第13.28 條以及香港法例第571章證券及期貨條例第XIVA部作出。 與武田製藥達成全球戰略合作，加速本公司新一代IO及ADC療法推向全 球市場 董事會欣然宣佈，於2025年10月22日（香港時間），信達生物與武田製藥（透過 武田製藥全資附屬公司Takeda Pharmaceuticals International AG）達成全球戰略 合作，旨在加速推進信達生物新一代IO及ADC療法開發，拓展全球市場價值。 本次合作包括兩款後期在研療法IBI363 (PD-1/IL-2α-bias)及IBI343 (CLDN18.2 ADC)，以及一款早期研發項目IBI3001 (EGFR/B7H3 ADC)的選擇權。 根據合作，信達生物與武田製藥將在全球範圍內 ...

Core Insights - Takeda Pharmaceutical Company Limited (NYSE:TAK) has entered a significant research partnership with US biotechnology company Nabla Bio to enhance the use of AI in drug delivery [1][2] - The partnership builds on a previous collaboration initiated in 2022, where Nabla will utilize its AI platform, the Joint Atomic Model (JAM), to develop protein-based treatments for Takeda's early-stage pipeline [2] - Takeda will make an upfront payment in double-digit millions to Nabla, with potential success-based payments exceeding $1 billion [3] Company Overview - Takeda Pharmaceutical Company Limited is a Japanese biotech firm focused on the research, development, and sale of pharmaceuticals, particularly in areas such as gastrointestinal, rare, immune, cancer, and neuropsychiatric diseases [4]